慢性阿片类药物使用与炎症性肠病生物制剂早期停用相关
结果显示慢性阿片类使用组生物制剂持续率更低(16.2% vs 33.5%,P<0.0001),且调整疾病严重度后早期停用生物制剂的风险增加23%(HR 1.23,95%CI 1.16-1.31)。
要点
- 慢性阿片类使用与IBD患者生物制剂持续率降低独立相关。
- 使用慢性阿片类的IBD患者医疗资源利用和合并症负担更高。
- 阿片戒断症状可能被误判为IBD复发,导致不恰当的生物制剂转换。
核心结论
- 慢性阿片类药物使用与炎症性肠病患者生物制剂停用风险增加相关。
主要发现
- 慢性阿片类使用组平均使用1.5种不同生物制剂,对照组为1.37种(P<0.0001)。
- 慢性阿片类使用组生物制剂持续至研究结束的比例为16.2%,对照组为33.5%(P<0.0001)。
- 慢性阿片类使用组医疗资源利用更多且合并症率更高。
- 调整疾病活动度相关指标后,慢性阿片类使用组生物制剂不持续的风险增加23%(HR 1.23;95%CI 1.16-1.31)。
临床怎么用
- 对IBD患者应评估慢性阿片类使用情况,其可能提示生物制剂早期停用风险。
- 当阿片类戒断症状疑似IBD复发时,需谨慎鉴别以避免不恰当的生物制剂转换。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chronic opioid use is associated with poorer clinical outcomes in inflammatory bowel disease. AIMS: To investigate an association between chronic opioid use and persistence with biologic agents in management of inflammatory bowel disease. METHODS: A total of 16 624 patients diagnosed with inflammatory bowel disease and receiving a first-time biologic prescription from 2011 to 2016 were identified retrospectively from the Truven MarketScan Database. A cohort of 1768 patients were identified as chronic opioid users utilising outpatient prescription claims. Utilisation patterns of biologic therapies were assessed from inpatient administration and outpatient claims data, including persistence calculations. Information on healthcare utilisation and common comorbidities was also collected. A Cox regression model was constructed to assess the hazard of chronic opioid use on early discontinuation of biologic therapy controlling for disease severity. RESULTS: A mean 1.5 different biologic agents were utilised by inflammatory bowel disease patients with chronic opioid use (vs 1.37 in the comparator group; P < 0.0001). A lower proportion of the chronic opioid use cohort persisted on biologic therapies to the end of the study period (16.2% vs 33.5% P < 0.0001). Inflammatory bowel disease patients with chronic opioid use utilised more healthcare resources and had a higher rate of comorbidities than the reference cohort. Patients with chronic opioid use were 23% more likely (hazard ratio 1.23; 95% CI [1.16-1.31]) to be non-persistent with biologic therapy while accounting for relevant markers of disease acuity. CONCLUSIONS: Chronic opioid use is associated with increased hazard of biologic discontinuation in inflammatory bowel disease. Symptoms of opioid withdrawal may mimic IBD flares thereby leading providers to inappropriately switch biologic therapies and compromise disease control.
引用
- Rhudy C, Perry CL, Singleton M, et al. Chronic opioid use is associated with early biologic discontinuation in inflammatory bowel disease. Aliment Pharmacol Ther. 2021. PMID: 33497484. doi:10.1111/apt.16269
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。